Cutaneous Adverse Reactions to Apalutamide: Case Series with Clinical and Pathological Correlations. [PDF]
Gil-Lianes J +9 more
europepmc +1 more source
Genetic Predictors of Progression and Skin Rash in Japanese mCSPC Patients Treated With Apalutamide: CUARTET Study. [PDF]
Shiota M +8 more
europepmc +1 more source
Trends in novel antiandrogen receptor signal inhibitor use and medical costs in prostate cancer. [PDF]
Miura H +12 more
europepmc +1 more source
Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide. [PDF]
Lowentritt BH +8 more
europepmc +1 more source
Real-world clinical usage and efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer: a multi-institutional study in the CsJUC. [PDF]
Tohi Y +23 more
europepmc +1 more source
Outcomes for [<sup>177</sup>Lu]Lu-PSMA-617 with and Without Concurrent Use of Androgen Receptor Pathway Inhibitors in Patients with Metastatic Castration-resistant Prostate Cancer. [PDF]
Muniz M +15 more
europepmc +1 more source
Real-World PSA Response and Overall Survival Among Men with mCSPC Receiving Apalutamide Versus Darolutamide (Both Without Docetaxel) in the US. [PDF]
Bilen MA +6 more
europepmc +1 more source
Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial. [PDF]
McHugh D +33 more
europepmc +1 more source
Real-world clinical outcomes of apalutamide versus abiraterone with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer. [PDF]
Pons-Fuster E +5 more
europepmc +1 more source

